Revance Therapeutics Inc Stock Ownership - Who owns Revance Therapeutics?

Insider buying vs selling

Have Revance Therapeutics Inc insiders been buying or selling?
Mark J. FoleyCEO2024-06-301,000$2.18
Tobin SchilkeCFO2024-06-301,000$2.18
Erica JordanChief Commercial Officer2024-04-162,392$3.80
Dwight MoxieCLO GC2024-03-188,125$5.04
Tobin SchilkeCFO2024-03-189,361$5.04
Dustin S. SjutsPresident2024-03-189,211$5.04
Dwight MoxieCLO GC2024-03-153,269$5.31
Mark J. FoleyCEO2024-03-1517,228$5.31
Mark J. FoleyCEO2024-03-153,305$5.31
Tobin SchilkeCFO2024-03-153,822$5.31

1 of 3

RVNC insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RVNC insiders and whales buy or sell their stock.

RVNC Shareholders

What type of owners hold Revance Therapeutics Inc stock?
Capital World Investors13.35%13,945,535$49.93MInstitution
Ronald W. Eastman7.55%7,885,294$28.23MInsider
Blackrock Inc7.00%7,312,479$26.18MInstitution
Franklin Resources Inc6.02%6,283,407$22.49MInstitution
Vanguard Group Inc5.17%5,398,406$19.33MInstitution
Palo Alto Investors LP5.02%5,248,004$18.79MInstitution
Essex Woodlands Health Ventures Fund Viii LP3.96%4,134,962$14.80MInsider
Polar Capital Holdings PLC3.72%3,884,819$13.91MInstitution
Jpmorgan Chase Co3.02%3,153,123$11.29MInstitution
Ronald J. Wooten2.96%3,096,650$11.09MInsider

1 of 3

RVNC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RVNC76.26%23.74%Net SellingNet Selling
ANRO59.01%25.03%Net BuyingNet Buying
ALXO75.66%24.34%Net SellingNet Selling
TRML54.37%45.63%Net Buying
VRCA40.75%59.25%Net Buying

Revance Therapeutics Stock Ownership FAQ

Who owns Revance Therapeutics?

Revance Therapeutics (NASDAQ: RVNC) is owned by 79.58% institutional shareholders, 24.77% Revance Therapeutics insiders, and 0.00% retail investors. Ronald W. Eastman is the largest individual Revance Therapeutics shareholder, owning 7.89M shares representing 7.55% of the company. Ronald W. Eastman's Revance Therapeutics shares are currently valued at $28.23M.

If you're new to stock investing, here's how to buy Revance Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.